@medchemexpress.bsky.social🎯#FDA approves #camizestrant (#Etcamah, AstraZeneca) + a CDK4/6 inhibitor for #ESR1-mutated HR+/HER2− advanced or metastatic breast cancer, using ctDNA to detect emerging resistance and guide a targeted treatment switch.
#FDAApproval #BreastCancer #ctDNA #PrecisionMedicine #Oncology
@sigtrans-sttt.bsky.socialWho benefits most from consolidation #Immunotherapy in limited-stage #SCLC?
Integrating #ctDNA status with tumor shrinkage identifies high-risk patients deriving survival benefit, while sustained ctDNA negativity predicts favorable outcomes.
@pmac-group.bsky.socialSERENA-6 provides prospective evidence that serial #ctDNA monitoring can detect emerging ESR1-mediated resistance and guide an endocrine switch before radiographic progression moving #LiquidBiopsy from detection to intervention.
@drtimos.bsky.social🚀 Get the #Oncology buzz from #ASCOGI25!
Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺
Download our full report! http://dlvr.it/TVJN5b
@ASCO
#SocialListening #LucidQuest
@rcatanho.bsky.socialDetección de DNA tumoral circulante libre de tejido pronostica recurrencia en pac c/CA mama triple negativo c/tiempos comparables c/pruebas multivariantes, apoya detección de enfermedad residual libre de tejido cuando no se dispone de tejido #ctDNA #TNBC jamanetwork.com/journals/jam...
@rcatanho.bsky.socialReducciones tempranas en el DNA tumoral circulante se asocian con una mejor supervivencia general independientemente del tipo del tumor y contexto terapéutico #ctDNA #OS #tumor ascopubs.org/doi/full/10....